First Retinnova Congress on efficacy and safety in the treatment of diabetic macular edema
Approximately 53 million adults suffer from diabetes in Europe today. It is estimated that by 2030 over 500 million people will be affected throughout the world. In Spain, one in every ten diabetic patients suffers from diabetic macular edema.
Today saw the start of the First Retinnova Congress in Madrid. The meeting will be attended by over 250 national and international expert retinologists who will debate efficacy and safety in the treatment of diabetic macular edema.
In this scientific meeting, which concludes tomorrow, the experts will be able to participate in talks and workshops. In addition, they can attend the presentation of clinical cases and revise the latest developments in disorders that affect the retina. This will concentrate on the visual impact caused by diabetic macular edema, age-related macular degeneration (AMD) of the exudative type and macular edema secondary to vein occlusion.
Organised by the pharmaceutical company Novartis, the Congress is led by Dr. Jordi Monés, the Director and ophthalmologist specialising in the macula, retina and the Medical Director of the Barcelona Macula Foundation: Research for vision.
Some of the experts who will showcase their expertise and experience are: Professor Anat Loewenstein of the Tel Aviv Medical Center in Israel, Dr. José Juan Escobar Barranco of the Dos de Maig Hospital in Barcelona, Dr. María Lafuente López-Herrera of the Morales Meseguer University General Hospital in Murcia, Dr. José Antonio López Garrido of Galdakao Hospital and Dr. José Luis Olea Vallejo of the Son Espases Hospital in Majorca, among others. In addition, they will enjoy the opportunity to attend the address by the keynote speaker, the prestigious consultant, advisor and business coach, Emilio Duró.
Dr. Jordi Monés, as well as coordinating this scientific meeting, will also give a lecture entitled “RVO: Pros and Cons of antiangiogenics”. The Doctor will provide evidence of ranibizumab in the management of macular edema secondary to retinal venous occlusion (RVO) in terms of efficacy and safety, he will define patient profiles where antiangiogenics demonstrate maximum efficacy and are the subject of dispute and he will present the experience of antiangiogenics in the treatment of macular edema secondary to retinal venous occlusion.